Regulatory

Examining the UK HTA Landscape for Orphan Medicines

To mark Rare Disease Day on 28 February, we’re sharing findings from our work examining how orphan new active substances (NASs) are assessed by two of the UK’s HTA [...]

2026-02-25T11:45:23+00:00February 26th, 2026|Tags: , , , |

HTA Submission Trends for EMA-Approved Oncology Medicines 2018-2023

How quickly do oncology medicines move from EMA approval to HTA submission across Europe — and how might this change under the EU HTA Regulation? At ISPOR Europe 2025, [...]

2026-01-07T16:23:29+00:00January 7th, 2026|Tags: , , , , |

Contribution of the ECOWAS region to the African Medicines Agency

“This book is a must-read for all those with interest in medicines regulation in Africa… It provides timely expert information for consideration and possible adoption during the operationalisation of [...]

2026-02-05T14:32:47+00:00November 7th, 2025|Tags: , , |
Go to Top